Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio
Executive Summary
Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.
You may also be interested in...
Europe's Biopharma Sector Could Be In For Bumper Year
The Belgian biotechs Ablynx and Galapagos are among the companies that are likely to have a very interesting 2018, according to analysts, and the sector in Europe as a whole is set for consolidation and more drugs getting to market, helped by a supportive regulatory landscape.
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.
Lilly's Bridge Builder, From Indiana To South Africa
Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.